Plasma pTau217 has demonstrated high accuracy in differentiating symptomatic Alzheimer’s disease (AD) from other neurodegenerative diseases [6, 7] and has positioned as one of the most promising plasma-based tau species [8–19]. This evidence concerns the gene MAPT and Alzheimer disease.